Healthtech

Q1 202415.02.2024

Longevity

Picture of Shubham Jaipuria

Shubham Jaipuria

at Sifted

There are a lot of crazy attempts to reverse ageing or to find an actual “cure” for dying, including gene-altering drugs, cell-reprogramming and cryogenic chambers. €500 a month longevity clinics could soon be the norm for the upper middle class in Europe. In 2023, longevity-specific startups raised $126m in Europe, declining from the $366m the sector pulled in 2022, in line with the overall slowdown in tech last year.

Silicon Valley heavyweights — techies including Larry Ellison and Jeff Bezos are spending big bucks on trying to beat death - at least by a couple of years. And big pharma is not just observing this from the sidelines. Novo Nordisk’s diabetes treatment Ozempic — arguably the world’s most famous drug — has shown promising results for repairing DNA damage in mice.

But even as tech progresses and wallets open, there’s a lot we don’t know about ageing or how to slow it: research still has a long way to go before it can show us that what works on mice will also work on humans.

20 most promising early-stage startups

Sifted score
8.4
-
Aware Health
Healthcare accessibility and employee well-being.
Strong investor(s)
Serial founder(s)
Hiring
- Year founded
  2021
- HQ
  Berlin, Germany
- Latest round
  Seed
  €10m / Jun 2022
- Total funding
  €14.1m
View company profile
Sifted score
7.71
-
Neko Health
Sensor-based AI for proactive healthcare.
Strong investor(s)
Serial founder(s)
Hiring
- Year founded
  2018
- HQ
  Stockholm, Sweden
- Latest round
  Series A
  €60m / Jul 2023
- Total funding
  €60m
View company profile
Sifted score
6.4
-
Biolytica
Real-time biosensor for optimising performance.
Hiring
- Year founded
  2021
- HQ
  Zug, Switzerland
- Latest round
  Seed
  €5.3m / May 2023
- Total funding
  €5.3m
View company profile
Sifted score
6.07
-
Bioniq
Personalized nutritional supplements for individuals.
Serial founder(s)
- Year founded
  2019
- HQ
  London, United Kingdom
- Latest round
  Early VC
  €13.6m / Mar 2022
- Total funding
  €20.7m
View company profile
Sifted score
5.79
-
GlycanAge
Biological age measurement using glycans.
Serial founder(s)
Hiring
- Year founded
  2020
- HQ
  Newcastle upon Tyne, United Kingdom
- Latest round
  Seed
  €3.8m / Aug 2022
- Total funding
  €4.2m
View company profile

Related Briefings

Related articles

HealthtechAnalysis

January 3, 2024

New year – longer life? What longevity has to offer in 2024

By Mimi Billing

October 31, 2023

Is this the over-the-counter alternative to “miracle drug” Ozempic?

Picture of Sigrid Therapeutics cofounder Sana Alajmovic

By Mimi Billing

HealthtechInterview

October 6, 2023

How to live into your 100s — diabetes drugs, sleep and mates

By Tim Smith

HealthtechAnalysis

September 8, 2023

Ozempic wars — how weight-loss drugs have become a new goldrush in healthtech

A tape measure and two injection pens.

By Tim Smith

August 1, 2023

Prima Materia makes third startup investment — into longevity

By Amy Lewin

HealthtechAnalysis

April 17, 2023

IV infusions and blood purification: Inside one of Europe’s first longevity clinics

Picture of Elisabeth Roider, chief medical officer at Maximon's longevity clinic.

By Mimi Billing

HealthtechAnalysis

October 10, 2022

Meet the company builders that think they can reverse ageing

Alexandra Bause is partner and cofounder of the longevity investor and company builder Apollo Health Ventures

By Mimi Billing